back to Australia directory
australia clinical guidance

Bronchiectasis (non-cystic fibrosis)

A detailed Australian summary of bronchiectasis (non-cystic fibrosis), with source-attributed priorities, a practical workflow, safety escalation and state or territory implementation boundaries.

JurisdictionAustralia
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Australia
This is an iatroX educational summary of named Australia sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Apply current TGA product information, PBS restrictions, state or territory law, local referral criteria, formulary and antimicrobial policy. A national recommendation does not create uniform service access.

Scope

Confirm bronchiectasis with compatible chronic productive cough or recurrent infection and high-resolution CT, then investigate an underlying cause. Obtain sputum microbiology when stable and during exacerbation, including prior Pseudomonas history, and tailor antimicrobials to culture and local policy. This summary is limited to the population, decisions and escalation boundaries stated in the named source.
sources for this section:TSANZ bronchiectasis

The Bottom Line

  • Confirm bronchiectasis with compatible chronic productive cough or recurrent infection and high-resolution CT, then investigate an underlying cause.
  • Obtain sputum microbiology when stable and during exacerbation, including prior Pseudomonas history, and tailor antimicrobials to culture and local policy.
  • Long-term macrolide therapy requires specialist selection, ECG, hearing and nontuberculous-mycobacteria assessment before initiation.
  • Teach regular airway-clearance technique through respiratory physiotherapy and address vaccination, exercise, nutrition and smoking.
sources for this section:TSANZ bronchiectasis

Practical clinical workflow

1

Topic-specific assessment action

Confirm bronchiectasis with compatible chronic productive cough or recurrent infection and high-resolution CT, then investigate an underlying cause.
2

Topic-specific diagnostic action

Teach regular airway-clearance technique through respiratory physiotherapy and address vaccination, exercise, nutrition and smoking.
3

Topic-specific management action

Frequent exacerbations, haemoptysis or declining lung function requires specialist review for eradication, suppressive or advanced therapies.
4

Topic-specific follow-through

Haemoptysis volume and trajectory should be documented and anticoagulation reviewed without delaying emergency transfer.
sources for this section:TSANZ bronchiectasis

Safety boundaries and escalation

  • Major haemoptysis, hypoxia, sepsis, respiratory failure or rapidly worsening symptoms requires urgent hospital and respiratory assessment.
  • Annual influenza, COVID-19 and indicated pneumococcal vaccination and pulmonary rehabilitation reduce preventable burden.
sources for this section:TSANZ bronchiectasis

Implementation

The named source is national or binational guidance used in Australia, but referral access, public-health directions, formularies and funded services can still differ by state, territory and health service. Check current TGA product information for medicines. Offer culturally safe care and use the NACCHO鈥揜ACGP National Guide where Aboriginal and Torres Strait Islander preventive or chronic-care recommendations differ.
sources for this section:TSANZ bronchiectasis

Clinical use boundary

This independently written summary is not an official guideline. Check the linked source version, current TGA-approved product information where medicines are involved, and the applicable state, territory and local pathway at the point of care.

sources for this section:TSANZ bronchiectasis

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Thoracic Society of Australia and New ZealandAustralian and New Zealand position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents and adultsDOI 10.1111/resp.14479 路 2023 position statement 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Australia question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.